Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer.

Nature communications·2026

Same author

Optimization of a parallel CAR for B-cell lymphoma via ITAM attenuation and target specificity validation.

Clinical and experimental immunology·2026

Same author

Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.

Cells·2026

Same author

Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells.

British journal of cancer·2026

Same author

Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease.

Human vaccines & immunotherapeutics·2026

Same author

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease.

Biology·2025

Search research articles

Related Experiment Video

Updated: Jun 20, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

CAR-T cell technologies that interact with the tumour microenvironment in solid tumours.

Chelsea Alice Taylor¹, Maya Glover¹, John Maher^1,2,3

¹Leucid Bio Ltd, Guy's Hospital, London, UK.

Expert Review of Clinical Immunology

|July 18, 2024

Summary

Chimeric antigen receptor (CAR) T-cell therapy shows promise for blood cancers but faces challenges in solid tumors. Engineering CAR T-cells with advanced strategies can improve their effectiveness against solid tumors.

Keywords:

Chimeric antigen receptor (CAR)cancer-associated fibroblasts (CAFs)chemokine receptors extracellular matrix (ECM)hypoxia immune checkpoint proteins tumor microenvironment (TME)tumor vasculature

More Related Videos

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jun 20, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Spheroid Killing Assay by CAR T Cells

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T-cells are effective against hematological malignancies.
CAR T-cell therapy has limited success in treating solid tumors.
Challenges include target selection, T-cell infiltration, and the tumor microenvironment.

Purpose of the Study:

To review recent advances in CAR T-cell technology for solid tumors.
To address challenges in CAR T-cell therapy for solid tumors.
To explore strategies for improving CAR T-cell efficacy in solid tumors.

Main Methods:

Literature review of PubMed database from 1987 to present.
Focus on studies detailing CAR T-cell engineering for solid tumors.
Analysis of strategies for tumor recruitment, infiltration, and overcoming immunosuppression.

Main Results:

CAR T-cells can be engineered with "armoring" strategies.
These strategies enhance trafficking to and infiltration of solid tumors.
Reversal of suppressive immune checkpoints is a key advancement.

Conclusions:

CAR T-cell therapy holds potential for solid tumors with further engineering.
Advanced strategies are crucial for overcoming solid tumor-specific challenges.
Future research should focus on optimizing CAR T-cells for solid tumor microenvironments.